AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02056119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer Arm
Description: * Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~* Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~* Aerosol treatment delivered per physician order.~* Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures.
Study NCT02056119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer Arm
Description: * Physician order received for subject, randomization to jet nebulizer occurred.~* Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~* Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~* Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures.
Study NCT01348854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFS Femtosecond Laser System
Description: arcuate incisions placed with the iFS femtosecond laser
Study NCT00865475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT+3TC+ABV (Trizivir)
Description: Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
Study NCT00865475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching to LPV/r monotherapy (Kaletra)
Description: Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
Study NCT02741011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radiological examination
Description: During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
Study NCT02613780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crosslinking
Description: corneal collagen crosslinking with riboflavin
Study NCT02613780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy
Study NCT02613780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign® Advanced WaveScan Studio
Description: Used to map wavefront aberration in planning photorefractive keratectomy
Study NCT03818308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir
Description: All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
Study NCT03605017 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Executive Function Training (VREFT)
Study NCT03605017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Executive Function Training (VREFT)
Study NCT00498277 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
Study NCT03614858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19/22
Description: Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19/22 cells/kg).
Study NCT04201951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid injection
Description: Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
Study NCT04201951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
Study NCT04201951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose water 5%
Description: Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
Study NCT04201951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose water 5%
Description: Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
Study NCT01260662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
Study NCT01260662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 Propofol/Ketamine
Description: Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
Study NCT01260662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4:1 Propofol/Ketamine
Description: Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
Study NCT04219293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling w/ and w/o PRP
Description: i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
Study NCT04219293 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Microneedling w/ and w/o PRP
Description: i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
Study NCT04157764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HomeChoice Claria APD machine with SHARESOURCE
Description: HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
Study NCT03904082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block ( Group ı)
Description: ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT03904082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane block ( Group ıı)
Description: SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT03904082 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (GROUPIII)
Description: Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study NCT04108689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACT
Description: An internet-based behavioral psychotherapy intervention to enhance athletic performance in elite ice hockey players.
Study NCT01455740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Visit Incentive (PVI)
Description: All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits.
Study NCT01455740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Choice (IC)
Description: All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits.
Study NCT02958228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Mental Imagery Training (PMIT)
Study NCT02958228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Control Training (CCT)
Study NCT02958228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study NCT02958228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Study NCT04323319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT, Graston Technique
Description: The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week.
Study NCT03458000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam UGI
Description: An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
Study NCT03458000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient was admitted to hospital for care and received in-patient EGD.
Study NCT02890082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen stim in early follicular phase
Description: Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~* Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~* Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~* Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia.
Study NCT02890082 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen stim in late follicular phase
Description: Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~* Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~* Ovulation induction by OVITRELLE® 250μg.~* Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia.
Study NCT02890082 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen stim in luteal phase
Description: Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~* 1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia
Study NCT02524210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole and Dabigatran
Description: omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
Study NCT01653366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Goal Setting
Description: Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them.
Study NCT02829983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Use of 500mg of Clarithromycin twice a day for 3 days
Study NCT01318083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
Study NCT01318083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
Study NCT02829983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo tablets twice a day for 3 days.
Study NCT01318083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
Study NCT01902797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
Study NCT03844633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Provera Injectable Product
Description: Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
Study NCT03844633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos -- Shot administered within 48 hours of childbirth
Study NCT03765346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone IR ADF
Description: Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
Study NCT03765346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone API powder
Description: Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
Study NCT02829983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-stage full-mouth ultrasonic debridement (FMUD)
Description: One session of Periodontal debridement using ultrasonic device.
Study NCT03765346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match oxycodone API powder
Description: Placebo to match oxycodone API powder (mass of 30 mg).
Study NCT02829983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: One-stage full-mouth ultrasonic debridement (FMUD)
Description: One session of Periodontal debridement using ultrasonic device.
Study NCT01765660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
Study NCT03765346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match oxycodone API powder
Description: Placebo to match oxycodone API powder (mass of 30 mg).
Study NCT03765346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match manipulated oxycodone IR ADF.
Description: Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single rocuronium dose
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single rocuronium dose
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repeated rocuronium dose
Study NCT01962298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous rocuronium infusion
Study NCT00246662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosaroxin
Description: All patients receive vosaroxin Injection
Study NCT02340962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
Study NCT01963832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02340962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
Study NCT02340962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Description: IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5.
Study NCT00070122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01963832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eCMIT
Study NCT01963832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual Care
Study NCT02172261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Study NCT04626921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: 30 mg of CNM-Au8
Study NCT03190083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-dimensional mammogram
Description: This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
Study NCT02172261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Study NCT01517178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New ostomy base plate (SS)
Description: The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
Study NCT01517178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care base plate
Description: The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
Study NCT04551586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0145228: Immediate Release
Description: ACH-0145228 (240 milligrams) will be administered orally on Day 1.